We are live on ! Find out more
VIA

Virtus Investment Advisers Portfolio holdings

AUM $363M
1-Year Est. Return 34.89%
This Fund
S&P 500
This Quarter Est. Return
+9.85%
1 Year Est. Return
+34.89%
3 Year Est. Return
+131.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$349M
AUM Growth
+$53.4M
Cap. Flow
+$36.4M
Cap. Flow %
10.41%
Top 10 Hldgs %
7.12%
Holding
478
New
39
Increased
273
Reduced
76
Closed
38

Top Buys

Rank Stock Value
1
OXLC
Oxford Lane Capital
OXLC
+$2.36M
2
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$1.99M
3
LRCX icon
Lam Research
LRCX
+$1.97M
4
IDXX icon
Idexx Laboratories
IDXX
+$1.96M
5
TKO icon
TKO Group
TKO
+$1.96M

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$1.85M
2
KKR icon
KKR & Co
KKR
+$1.62M
3
UAL icon
United Airlines
UAL
+$1.62M
4
CBRE icon
CBRE Group
CBRE
+$1.61M
5
NU icon
Nu Holdings
NU
+$1.58M

Sector Composition

Rank Sector Weight
1 Financials 33.25%
2 Healthcare 17.27%
3 Technology 14.61%
4 Industrials 8.9%
5 Consumer Discretionary 5.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QURE icon
226
uniQure
QURE
$3.2B
$415K 0.12%
7,116
+1,235
+21% +$22.4K
OXSQ icon
227
Oxford Square Capital
OXSQ
$153M
$397K 0.11%
249,916
+29,428
+13% +$64.7K
MSIF
228
MSC Income Fund Inc
MSIF
$551M
$396K 0.11%
+30,158
New +$449K
GERN icon
229
Geron
GERN
$949M
$390K 0.11%
284,868
– –
GLAD icon
230
Gladstone Capital
GLAD
$439M
$387K 0.11%
17,698
-4,435
-20% -$117K
NCDL icon
231
Nuveen Churchill Direct Lending
NCDL
$615M
$387K 0.11%
28,008
+5,555
+25% +$88.9K
LEGN icon
232
Legend Biotech
LEGN
$4.01B
$382K 0.11%
11,722
– –
VRTX icon
233
Vertex Pharmaceuticals
VRTX
$135B
$378K 0.11%
966
– –
HRMY icon
234
Harmony Biosciences
HRMY
$2.27B
$367K 0.11%
13,333
– –
ZLAB icon
235
Zai Lab
ZLAB
$2.61B
$350K 0.1%
10,328
– –
IBRX icon
236
ImmunityBio
IBRX
$7.87B
$343K 0.1%
139,309
– –
RARE icon
237
Ultragenyx Pharmaceutical
RARE
$2.59B
$340K 0.1%
11,311
– –
BCRX icon
238
BioCryst Pharmaceuticals
BCRX
$2.45B
$324K 0.09%
42,730
– –
RAPP
239
Rapport Therapeutics
RAPP
$2.21B
$303K 0.09%
10,214
+1,773
+21% +$31.6K
ADMA icon
240
ADMA Biologics
ADMA
$2.18B
$302K 0.09%
20,574
– –
MLYS icon
241
Mineralys Therapeutics
MLYS
$2.39B
$289K 0.08%
7,626
+1,324
+21% +$28.6K
OLMA icon
242
Olema Pharmaceuticals
OLMA
$1.05B
$274K 0.08%
28,026
+4,865
+21% +$29.2K
TRML
243
DELISTED
Tourmaline Bio
TRML
$273K 0.08%
5,718
+993
+21% +$27.5K
ARWR icon
244
Arrowhead Research
ARWR
$12.5B
$242K 0.07%
7,015
+1,218
+21% +$26.8K
NTLA icon
245
Intellia Therapeutics
NTLA
$1.69B
$235K 0.07%
13,627
+2,366
+21% +$29.1K
NUVB icon
246
Nuvation Bio
NUVB
$2.28B
$233K 0.07%
62,866
+10,914
+21% +$29.7K
DNTH icon
247
Dianthus Therapeutics
DNTH
$6.09B
$232K 0.07%
5,899
+1,024
+21% +$26.2K
SRPT icon
248
Sarepta Therapeutics
SRPT
$1.77B
$230K 0.07%
11,911
– –
CNTA
249
DELISTED
Centessa Pharmaceuticals
CNTA
$229K 0.07%
9,451
+1,641
+21% +$29.2K
COGT icon
250
Cogent Biosciences
COGT
$7.11B
$226K 0.06%
15,760
+2,736
+21% +$32.4K
8 9
10
11 12

Similar funds

WI
WBI Investments Red Bank, New Jersey $362M AUM 23.75% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
HS
HighVista Strategies Boston, Massachusetts $362M AUM 230.96% 1-Year Est. Return
SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return
RGC
Roberts, Glore & Co Deerfield, Illinois $364M AUM 19.54% 1-Year Est. Return

Virtus Investment Advisers's Q3 2025 Portfolio in Review

As of Q3 2025, Virtus Investment Advisers held 478 positions worth $349M, up 18% from $296M the previous quarter. Its ten largest holdings account for 7.1% of the portfolio.

Virtus Investment Advisers deployed $36.4M of net new capital in Q3 2025, opening 39 new positions and adding to 273 existing holdings. Its largest new stake was Oxford Lane Capital: 129,209 shares worth $2.19M.

By sector, the portfolio is most concentrated in Financials at 33% of assets, up from 33% a quarter earlier, followed by Healthcare and Technology.

On the sell side, the largest reduction was Incyte, an estimated $1.85M trimmed.

  • Virtus Investment Advisers's largest Q3 2025 buy was Oxford Lane Capital: 129,209 shares worth $2.19M.
  • Virtus Investment Advisers added most to Prospect Capital in Q3 2025, an estimated $697K increase.
  • Virtus Investment Advisers's biggest Q3 2025 reduction was Incyte, cutting an estimated $1.85M.
  • Virtus Investment Advisers fully exited KKR & Co in Q3 2025, selling an estimated $1.62M.
  • Virtus Investment Advisers's ten largest holdings make up 7.1% of its $349M portfolio in Q3 2025.
  • Virtus Investment Advisers opened 39 new positions and closed 38 in Q3 2025.
  • Virtus Investment Advisers's portfolio value rose 18% quarter-over-quarter to $349M.

Based on Virtus Investment Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.